pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,347 catalysts · 5,347 phase readout · 2,338 8k filing · 343 pdufa · 256 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 0 catalysts2026-07-31: 0 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: drug expiry×type: phase readout×clear all
type
  • phase readout5,347
  • 8k filing2,338
  • pdufa343
  • earnings256
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›RECRUITINGphase readoutNCT07426757: An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Sponsor: Pfizer. Phase: PHASE1. Conditions: Advanced Malignancies, Advanced Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT06165601: Proteinuria in Renal Transplant Patients Treated With Dapagliflozin

Sponsor: University Hospital, Montpellier. Phase: NA. Conditions: Chronic Kidney Diseases

full page →ctgov ↗
›WITHHELDphase readoutNCT06546501: [Trial of device that is not approved or cleared by the U.S. FDA]

Sponsor: [Redacted]. Phase: . Conditions:

full page →ctgov ↗
›RECRUITINGphase readoutNCT05876312: Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Sponsor: ADARx Pharmaceuticals, Inc.. Phase: PHASE1. Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07569419: Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

Sponsor: University of Nottingham. Phase: EARLY_PHASE1. Conditions: Cystic Fibrosis (CF)

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06965465: A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

Sponsor: Pfizer. Phase: PHASE1. Conditions: Healthy

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05023967: Metformin and Nightly Fasting in Women With Early Breast Cancer

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT07618507: Resistance Profile to Antiretroviral Medications in Individuals Living With HIV Who Failed a First-Line Regimen With Tenofovir / Lamivudina and Dolutegravir in Brasil

Sponsor: Federal University of São Paulo. Phase: NA. Conditions: HIV, HIV -1 Infection

full page →ctgov ↗
›TERMINATEDphase readoutNCT03968107: Diagnostic Performance of Antenatal Ultrasound for High-Risk Intestinal Malrotation

Sponsor: University Hospital, Montpellier. Phase: . Conditions: Pregnancy Related

full page →ctgov ↗
›RECRUITINGphase readoutNCT07413692: BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women

Sponsor: BTL Industries Ltd.. Phase: NA. Conditions: Depressive Symptoms, Urinary Incontinence

full page →ctgov ↗
›RECRUITINGphase readoutNCT05461092: Regional Nerve Blocks to Improve Analgesia and Recovery in Older Adults Undergoing Spinal Fusion

Sponsor: University of Iowa. Phase: EARLY_PHASE1. Conditions: Delirium, Pain, Back, Spinal Fusion, Thoracolumbar Interfascial Plane Block

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07505836: Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

Sponsor: Sinovac Biotech Co., Ltd. Phase: PHASE3. Conditions: Epidemic Meningitis, Meningococcal Vaccines

full page →ctgov ↗
›RECRUITINGphase readoutNCT07382336: A Mobile Application for Early Detection and Symptoms Trajectories of Postpartum Depression Using Ecological Momentary Assessment (EMA)

Sponsor: The Hong Kong Polytechnic University. Phase: . Conditions: Postpartum Depression (PPD)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07605936: Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study

Sponsor: University of Limerick. Phase: . Conditions: Frailty at Older Adults, Prostate Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07244211: MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)

Sponsor: University of Southern California. Phase: NA. Conditions: Femoral Neck Fractures

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04633811: Effect of Weight Loss on Urinary Oxalate Excretion in Obese Calcium Oxalate Kidney Stone Formers

Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Kidney Stone

full page →ctgov ↗
›RECRUITINGphase readoutNCT07197944: Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Sponsor: Zealand Pharma. Phase: PHASE3. Conditions: Short Bowel Syndrome

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06894849: Text -Based Depression Screening Among Cancer Survivors

Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Cancer, Depression Secondary to Other Disease, Cancer Survivor

full page →ctgov ↗
›RECRUITINGphase readoutNCT06045338: Mind Body Intervention for Long COVID-19

Sponsor: Beth Israel Deaconess Medical Center. Phase: NA. Conditions: Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07494058: A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico

Sponsor: Takeda. Phase: . Conditions: Lysosomal Disease

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03253848: Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia

Sponsor: ECOG-ACRIN Cancer Research Group. Phase: NA. Conditions: Acute Promyelocytic Leukemia With PML-RARA, t(15;17)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07394855: Mechanisms of Persistent Fatigue

Sponsor: University Hospital, Akershus. Phase: . Conditions: Fatigue Post Viral

full page →ctgov ↗
›COMPLETEDphase readoutNCT07249658: Effects of Power and High-Intensity Gait Training for Functional Mobility an Ambulation in Chronic Stroke

Sponsor: Riphah International University. Phase: NA. Conditions: Stroke

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sponsor: Genmab. Phase: PHASE3. Conditions: Diffuse Large B-Cell Lymphoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07257055: Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Phase 2 Study, MCL, BTKi, Rituximab, Glofitamab

full page →ctgov ↗
›COMPLETEDphase readoutNCT03315455: Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants

Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Hemophilia A

full page →ctgov ↗
›COMPLETEDphase readoutNCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Overweight, Obesity

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT06285448: Feasibility of Lecanemab Registry and Clinical Outcome Measures

Sponsor: HealthPartners Institute. Phase: . Conditions: Alzheimer Disease

full page →ctgov ↗
›RECRUITINGphase readoutNCT06507748: A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Sponsor: National Cancer Institute (NCI). Phase: NA. Conditions: Neurofibromatosis Type 1

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT06720948: The ION Facet Screw System Ambispective Evaluation

Sponsor: SurGenTec LLC. Phase: . Conditions: Intra-facet ION 3D Facet Screw System

full page →ctgov ↗
›RECRUITINGphase readoutNCT04365855: The Olmsted NAFLD Epidemiology Study (TONES)

Sponsor: Mayo Clinic. Phase: NA. Conditions: Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis

full page →ctgov ↗
›COMPLETEDphase readoutNCT03787355: Clinical Evaluation of Vertical Inter-implant Papilla Height in Platform Matched Implants in Comparison to Morse Connection Abutments

Sponsor: Cairo University. Phase: NA. Conditions: Interimplant Mucosa

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05821855: A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China

Sponsor: AbbVie. Phase: PHASE4. Conditions: Open-angle Glaucoma, OAG

full page →ctgov ↗
›COMPLETEDphase readoutNCT04184648: Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants

Sponsor: Wang Jianhui. Phase: . Conditions: Bronchopulmonary Dysplasia

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07630948: Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer

Sponsor: Institute of Oncology Ljubljana. Phase: PHASE4. Conditions: Breast Cancer, Adherence, Medication

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07595848: Integration of Wearable Sensor Devices Into a Single System to Predict the Onset of Sepsis

Sponsor: Check Point R & D Ltd. Phase: NA. Conditions: Sepsis

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT07439055: Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A

Sponsor: Chulalongkorn University. Phase: PHASE2. Conditions: Hemophilia A Patient

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07613255: Evaluating Metabolic Health in Individuals With Extreme Obesity

Sponsor: Pennington Biomedical Research Center. Phase: . Conditions: BMI>40

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04567355: Migraine Manager (R01)

Sponsor: Children's Hospital Medical Center, Cincinnati. Phase: PHASE2. Conditions: Migraine, Migraine Disorders

full page →ctgov ↗
›RECRUITINGphase readoutNCT06824155: HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

Sponsor: Radiopharm Theranostics, Ltd. Phase: EARLY_PHASE1. Conditions: HER2 Gene Mutation, Advanced Solid Tumors

full page →ctgov ↗
›TERMINATEDphase readoutNCT03630055: Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Sponsor: Ottawa Heart Institute Research Corporation. Phase: PHASE3. Conditions: Radial Artery Occlusion

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07137455: EDEN Intracardiac Electrogram Recording and Classifying System

Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: NA. Conditions: Ventricular Arrhythmia

full page →ctgov ↗
›RECRUITINGphase readoutNCT05837455: NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

Sponsor: Washington University School of Medicine. Phase: PHASE2. Conditions: Breast Cancer, Cancer of the Breast

full page →ctgov ↗
›RECRUITINGphase readoutNCT07436455: F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Sponsor: Ankara University. Phase: NA. Conditions: Thyroid Cancer, Differentiated Thyroid Cancer

full page →ctgov ↗
›RECRUITINGphase readoutNCT07464938: New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Phase: NA. Conditions: Cardiac Arrest (CA)

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07590648: Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia

Sponsor: Hospital Universitari Vall d'Hebron Research Institute. Phase: PHASE4. Conditions: Febrile Neutropenia (FN), Pediatric Cancer, Hematologic Malignancies, Solid Tumors, Invasive Bacterial Infection

full page →ctgov ↗
›RECRUITINGphase readoutNCT02896348: Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors

Sponsor: Spaulding Rehabilitation Hospital. Phase: NA. Conditions: Stroke, Hemiparesis

full page →ctgov ↗
›RECRUITINGphase readoutNCT06254248: Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma

Sponsor: Assistance Publique - Hôpitaux de Paris. Phase: PHASE2. Conditions: Liver Transplant, Hepatocellular Carcinoma Recurrent, Systemic Treatment

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07369349: Artificial Int: Neurogenic Bowel Education in Spinal Cord Injury Patients

Sponsor: Senem Duman. Phase: NA. Conditions: Spinal Cord Injury, Neurogenic Bowel Dysfunction

full page →ctgov ↗
›RECRUITINGphase readoutNCT05159349: Mental Health During the Whole Life Cycle of Community Patients With Schizophrenia

Sponsor: Shanghai Mental Health Center. Phase: . Conditions: Schizophrenia

full page →ctgov ↗
← prev
page 52 of 107
next →